THC Biomed Intl Ltd. (THCBF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTHC Biomed Intl Ltd. (THCBF) trades at $0.001. THC Biomed Intl Ltd. operates in the Canadian cannabis market, producing and selling medical and recreational cannabis products. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for THCBF: THCBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
THC Biomed Intl Ltd. (THCBF) Healthcare & Pipeline Overview
THC Biomed Intl Ltd. is a Canadian cannabis company focused on producing and distributing medical and recreational cannabis products, including beverages, edibles, and pure cannabis sticks under the THC KISS brand, operating in a competitive and evolving regulatory landscape with a current negative profit margin.
What Is the Investment Thesis for THCBF?
Investing in THC Biomed Intl Ltd. (THCBF) presents a high-risk, high-reward scenario. The company's negative profit margin of -91.8% and gross margin of -30.8% indicate significant challenges in achieving profitability. Growth catalysts include potential expansion of its product line and increased market penetration within Canada. However, the company's small market capitalization and negative beta of -0.36 suggest high volatility and sensitivity to market fluctuations. The absence of a dividend further underscores the speculative nature of this investment. Investors should carefully consider the company's financial performance, competitive landscape, and regulatory risks before investing.
Based on FMP financials and quantitative analysis
THCBF Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
- P/E Ratio of -1.07 reflects negative earnings, suggesting the company is currently not profitable.
- Profit Margin of -91.8% highlights significant challenges in achieving profitability and managing expenses.
- Gross Margin of -30.8% indicates that the company's cost of goods sold exceeds its revenue, raising concerns about its pricing strategy and operational efficiency.
- Beta of -0.36 suggests the stock price is negatively correlated with the market, potentially offering downside protection during market downturns but also limiting upside potential during bull markets.
Who Are THCBF's Competitors?
THCBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AVTBF Avant Brands Inc. | $0.36 | -7.87% | $5.48M | — |
| BBRRF Blueberries Medical Corp. | $0.01 | +19.00% | $5.89M | — |
| CPIVF Captiva Verde Wellness Corp. | $0.06 | 0.00% | $19.2M | — |
| TAK Takeda Pharmaceutical Company Limited | $17.86 | 0.00% | $56.8B | — |
| TEVA Teva Pharmaceutical Industries Limited | $39.53 | +0.56% | $46.0B | — |
| HLN Haleon plc | $8.80 | +0.92% | $38.8B | — |
| ZTS Zoetis Inc. | $69.69 | +0.85% | $29.2B | — |
| VTRS Viatris Inc. | $17.60 | +0.80% | $20.5B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are THCBF's Key Strengths?
Established brand presence with THC KISS products.
- Early mover advantage in the Canadian cannabis market.
- Diverse product portfolio including beverages, edibles, and cannabis sticks.
- Production and distribution capabilities within Canada.
What Are THCBF's Weaknesses?
Negative profit margin and gross margin.
- Small market capitalization and limited financial resources.
- High dependence on the Canadian market.
- Limited brand recognition compared to larger competitors.
What Are the Key Risks for THCBF?
Financial-distress signal — its Altman Z-Score of -3.67 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-36.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger, more established cannabis companies.
- Evolving regulations and changing consumer preferences.
- Increased taxes and regulatory burdens on the cannabis industry.
- Fluctuations in cannabis prices and supply.
- Limited access to capital and financing options.
What Are THCBF's Competitive Advantages?
- Brand recognition through the THC KISS brand.
- Established distribution network in Canada.
- Proprietary formulations for cannabis-infused products.
- Early mover advantage in the Canadian cannabis market.
What Does THCBF Do?
THC Biomed Intl Ltd., founded in 2012 and headquartered in Kelowna, Canada, is a cannabis company focused on the production and sale of medical and recreational cannabis. The company's product portfolio includes a variety of cannabis products, such as cannabis beverage shots, gummies, and biscuits marketed under the THC KISS brand. Additionally, THC Biomed offers pure cannabis sticks. The company operates within the Canadian cannabis market, navigating a complex regulatory environment. THC Biomed's strategy involves developing and marketing diverse cannabis products to cater to both medical and recreational users. The company aims to establish a strong brand presence in the Canadian market through its THC KISS line and other product offerings. As a relatively small player in the broader cannabis industry, THC Biomed faces competition from larger, more established companies. The company's success depends on its ability to innovate, maintain product quality, and effectively market its products to consumers and medical patients. THC Biomed continues to explore opportunities for growth and expansion within the evolving Canadian cannabis market.
What Products and Services Does THCBF Offer?
- Produces and sells medical cannabis in Canada.
- Produces and sells recreational cannabis in Canada.
- Offers cannabis beverage shots under the THC KISS brand.
- Offers cannabis gummies under the THC KISS brand.
- Offers cannabis biscuits under the THC KISS brand.
- Offers pure cannabis sticks.
How Does THCBF Make Money?
- Cultivates and processes cannabis.
- Manufactures cannabis-infused products.
- Distributes products through authorized retailers.
- Generates revenue through the sale of cannabis and cannabis-infused products.
What Industry Does THCBF Operate In?
THC Biomed Intl Ltd. operates within the rapidly evolving Canadian cannabis industry. The market is characterized by increasing competition, evolving regulations, and shifting consumer preferences. Companies in this sector face challenges related to production costs, distribution, and marketing. The Canadian cannabis market is projected to continue growing, driven by increasing acceptance and legalization of cannabis products. THC Biomed competes with larger, more established players in the industry, including companies with greater financial resources and broader distribution networks. The company's success depends on its ability to differentiate its products, effectively manage costs, and navigate the complex regulatory landscape.
Who Are THCBF's Key Customers?
- Medical cannabis patients in Canada.
- Recreational cannabis consumers in Canada.
- Authorized cannabis retailers in Canada.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Forward Outlook
Wall Street analysts project THC Biomed Intl Ltd. revenue of about $3.1M for fiscal 2026, with EPS near $-0.02.
Key Financial Metrics
Return on equity for THC Biomed Intl Ltd. stands at -36.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -61.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.63 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -93.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
THC Biomed Intl Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.67 places it in the distress zone, a signal of elevated financial risk.
Company Profile
THC Biomed Intl Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Kelowna, CA. The company is led by CEO John Miller. THCBF has traded publicly since 2018.
THCBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
THCBF Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
There's A New Cannabis Index To Help Investors Measure The Industry
· Jun 27, 2019
THCBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for THCBF.
Price Targets
Wall Street price target analysis for THCBF.
THCBF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for THCBF; grades run from A+ (80-100) to F (below 30).
Leadership: John Miller
CEO
John Miller is the CEO of THC Biomed Intl Ltd. He is responsible for managing the company's overall operations and strategic direction. His background includes experience in the cannabis industry. He oversees the company's production, distribution, and marketing efforts, ensuring compliance with regulations and driving growth. Mr. Miller's leadership is focused on expanding THC Biomed's market share and developing innovative cannabis products.
Track Record: Under John Miller's leadership, THC Biomed Intl Ltd. has focused on expanding its product line and increasing its market presence in Canada. Key milestones include the launch of the THC KISS brand and the development of new cannabis-infused products. He is managing 35 employees. The company has faced challenges related to profitability and competition in the evolving cannabis market.
THCBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that THC Biomed Intl Ltd. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited liquidity, lack of transparency, and increased volatility compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of transparency due to limited financial disclosure.
- Higher price volatility compared to exchange-listed stocks.
- Potential for market manipulation and fraud.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Check for any red flags or warning signs, such as unusual trading activity or negative news.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 2012.
- The company has a website and actively markets its products.
- The company has a physical headquarters in Kelowna, Canada.
- The company produces and sells cannabis products under the THC KISS brand.
- The company is managed by CEO John Miller.
What Investors Ask About THC Biomed Intl Ltd. (THCBF) — Healthcare
What does THC Biomed Intl Ltd. do?
THC Biomed Intl Ltd. is a Canadian cannabis company that produces and sells both medical and recreational cannabis products. Their offerings include a variety of cannabis-infused products such as beverage shots, gummies, and biscuits under the THC KISS brand, as well as pure cannabis sticks.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- Analyst coverage is not available for this stock.
- OTC market investments carry higher risks.